Joseph Pidala

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. doi request reprint Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida Oncologic Sciences, College of Medicine at University of South Florida, Tampa, Florida Electronic address
    Biol Blood Marrow Transplant 21:1074-82. 2015
  2. pmc Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, USA Oncologic Sciences, College of Medicine at University of South Florida, USA
    Haematologica 100:970-7. 2015
  3. pmc Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium
    Joseph Pidala
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 19:967-72. 2013
  4. pmc Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study
    Joseph Pidala
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Biol Blood Marrow Transplant 19:784-91. 2013
  5. pmc Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization
    J Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Bone Marrow Transplant 48:346-50. 2013
  6. pmc Practice variation in physician referral for allogeneic hematopoietic cell transplantation
    J Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Bone Marrow Transplant 48:63-7. 2013
  7. pmc A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, FOB 3308, Tampa, FL 33612, USA
    Haematologica 97:1882-9. 2012
  8. pmc Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study
    Joseph Pidala
    Moffitt Cancer Center, Tampa, FL, USA
    Haematologica 97:451-8. 2012
  9. pmc Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
    Joseph Pidala
    Moffitt Cancer Center, Tampa, FL, USA
    Blood 117:4651-7. 2011
  10. ncbi request reprint Graft-vs-host disease following allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Blood and Marrow Transplant Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 18:268-76. 2011

Detail Information

Publications47

  1. doi request reprint Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida Oncologic Sciences, College of Medicine at University of South Florida, Tampa, Florida Electronic address
    Biol Blood Marrow Transplant 21:1074-82. 2015
    ..Ofatumumab in combination with prednisone is safe and a phase II examination of efficacy is ongoing. ..
  2. pmc Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, USA Oncologic Sciences, College of Medicine at University of South Florida, USA
    Haematologica 100:970-7. 2015
    ..Further study of determinants of successful immune suppression discontinuation is needed. ..
  3. pmc Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium
    Joseph Pidala
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 19:967-72. 2013
    ..However, change in 2MWT is not sensitive to chronic GVHD response, limiting its usefulness in clinical trials...
  4. pmc Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study
    Joseph Pidala
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Biol Blood Marrow Transplant 19:784-91. 2013
    ....
  5. pmc Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization
    J Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Bone Marrow Transplant 48:346-50. 2013
    ..Further efforts are needed to enhance effective donor identification and transplant utilization, particularly in non-Caucasian ethnic groups...
  6. pmc Practice variation in physician referral for allogeneic hematopoietic cell transplantation
    J Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Bone Marrow Transplant 48:63-7. 2013
    ..These data speak to important factors relevant to HCT referral practices, and highlight several opportunities for education and intervention to reduce current disparities...
  7. pmc A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, FOB 3308, Tampa, FL 33612, USA
    Haematologica 97:1882-9. 2012
    ..Sirolimus-based immune suppression may suppress alloreactive T cells, while sparing the survival and function of regulatory T cells...
  8. pmc Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study
    Joseph Pidala
    Moffitt Cancer Center, Tampa, FL, USA
    Haematologica 97:451-8. 2012
    ..The National Institutes of Health Consensus Conference proposed the term "overlap" graft-versus-host disease to describe the situation when both acute and chronic graft-versus-host disease are present...
  9. pmc Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
    Joseph Pidala
    Moffitt Cancer Center, Tampa, FL, USA
    Blood 117:4651-7. 2011
    ..Compromised QOL provides a functional assessment of the effects of chronic GVHD, and may be measured in cGVHD clinical studies using either the SF-36 or the FACT-BMT...
  10. ncbi request reprint Graft-vs-host disease following allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Blood and Marrow Transplant Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 18:268-76. 2011
    ..However, it is complicated by the syndromes of acute and chronic graft-vs-host disease (GVHD)...
  11. pmc The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612 USA
    Haematologica 96:1678-84. 2011
    ..The 2005 National Institutes of Health Consensus Development Conference on chronic graft-versus-host disease proposed major changes in the classification and grading of severity of chronic graft-versus-host disease...
  12. pmc Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Haematologica 96:1528-35. 2011
    ....
  13. pmc Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612 USA
    Haematologica 96:1351-6. 2011
    ..Advances in acute graft-versus-host disease therapy are needed...
  14. pmc Variation in management of immune suppression after allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 17:1528-36. 2011
    ..These data argue for more rigorous study of IS management post-HCT so that evidence-based practice guidelines can be developed...
  15. doi request reprint ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 17:1237-44. 2011
    ..A regimen of ATG 7.5 mg/kg total ending on day -1 effectively decreased the occurrence of grade III-IV aGVHD and severe chronic GVHD...
  16. pmc Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Departments of Blood and Marrow Transplantation and Oncological Sciences, University of South Florida, Moffitt Cancer Center, Tampa, FL 33612 9416
    Biol Blood Marrow Transplant 15:881-5. 2009
    ..Sirolimus was well tolerated with mild and reversible thrombotic microangiopathy occurring in 2 patients. This experience provides preliminary evidence for the efficacy of sirolimus as a sole primary therapy in the treatment of aGVHD...
  17. ncbi request reprint Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
    Ann Transplant 15:21-9. 2010
    ..We aimed to characterize the activity of pentostatin as rescue therapy for refractory GVHD...
  18. pmc Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Hematol Oncol 3:36. 2010
    ..However, multivariable analysis did not demonstrate significant differences in overall survival (p = 0.78) or non-relapse mortality (p = 0.6) according to conditioning regimen delivered...
  19. doi request reprint Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity
    J Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA
    Bone Marrow Transplant 46:641-9. 2011
    ..Importantly, there was no effect of age. t-i.v. BU/Flu provides effective disease control with encouraging NRM in patients up to age of 70 years...
  20. doi request reprint Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida, USA
    Biol Blood Marrow Transplant 17:239-48. 2011
    ..These data suggest an independent adverse effect of dysglycemia in patients treated with glucocorticoids for aGVHD, and argue for stringent glycemic control in this setting...
  21. doi request reprint Glucocorticoid-refractory acute graft-versus-host disease
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida, USA
    Biol Blood Marrow Transplant 16:1504-18. 2010
    ....
  22. pmc Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?
    Joseph Pidala
    Departmentsof Blood and Marrow Transplantation, Moffitt Cancer Center and Oncological Sciences, University of South Florida, Tampa, FL 33612 9416, USA
    Haematologica 95:660-5. 2010
    ....
  23. doi request reprint Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Biol Blood Marrow Transplant 16:729-38. 2010
    ....
  24. doi request reprint A case of acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13)
    Joseph Pidala
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9416, USA
    Cancer Genet Cytogenet 182:46-9. 2008
    ..A case is presented of ABL arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13). Discussion includes a literature review...
  25. doi request reprint Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9416, USA
    Biol Blood Marrow Transplant 15:1415-21. 2009
    ..PBSC is the optimal stem cell source in terms of both overall and quality-adjusted life expectancy, except in conditions with a very low relapse probability, in which BM provides optimal outcomes...
  26. doi request reprint Infliximab for managing steroid-refractory acute graft-versus-host disease
    Joseph Pidala
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Biol Blood Marrow Transplant 15:1116-21. 2009
    ..4 for death in those without CR (95% CI=3.6 to 19.6; P < .0001). This series demonstrates the limited activity of infliximab in patients with high-grade aGVHD. Further work is needed to identify effective therapy for aGVHD...
  27. doi request reprint Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease
    J Pidala
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612 9416, USA
    Bone Marrow Transplant 45:919-24. 2010
    ..04-0.39), P=0.0004) were significant predictors of OS. MMF was overall well tolerated, with only two patients requiring discontinuation for myelosuppression. MMF shows activity in the salvage of steroid-refractory, grades I-II aGVHD...
  28. pmc Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Biol Blood Marrow Transplant 19:1087-93. 2013
    ..Two-year PFS was 55%, and OS was 68%. This regimen ensures durable engraftment, is effective against persistent disease, and results in relatively low mortality from causes other than relapse...
  29. doi request reprint Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, FOB 3, Tampa, FL 33612, USA
    Int J Hematol 93:206-12. 2011
    ..The addition of rituximab 375 mg/m(2) to t-IV Bu/Flu does not appear to adversely affect engraftment, donor chimerism, or increase the risk of infectious complications...
  30. pmc Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
    Taiga Nishihori
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Br J Haematol 157:553-63. 2012
    ..Bortezomib combined with high-dose melphalan is a well-tolerated conditioning with some activity in patients with resistant myeloma...
  31. pmc Quality of life after allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Blood 114:7-19. 2009
    ..Behavioral interventions show promise to maintain or improve quality of life after allogeneic HCT. The review concludes with recommendations to investigators and clinicians as the state of this research advances...
  32. doi request reprint IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation
    Brian C Betts
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, USA
    Haematologica . 2017
    ..However, an approach to target STAT3 is needed to enhance graft-versus-host disease prevention (NCT01927120)...
  33. pmc Have we improved in preventing and treating acute graft-versus-host disease?
    Lia Perez
    Department of Oncological Sciences, University of South Florida, Florida, USA
    Curr Opin Hematol 18:408-13. 2011
    ..Accordingly, progress in the prevention and primary therapy of this complication is needed to improve patient outcomes...
  34. pmc Tolerance associated gene expression following allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, United States of America
    PLoS ONE 10:e0117001. 2015
    ..These data suggest that differential gene expression can be utilized to accurately classify tolerant patients following HCT. Prospective investigation of immune tolerance biologic markers is warranted. ..
  35. pmc Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality
    Joseph Pidala
    H Lee Moffitt Cancer Center, Tampa, FL
    Blood 122:3651-8. 2013
    ..78, 95% = CI 1.27-2.51, P = .0009). These results demonstrate that donor-recipient mismatch for certain peptide-binding residues of the HLA class I molecule is associated with increased risk for acute and chronic GVHD and death. ..
  36. pmc Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention
    Joseph Pidala
    Department of Blood and Marrow Transplantation, University of South Florida, Tampa, FL, USA
    Br J Haematol 148:373-85. 2010
    ..We then discuss evidence in support of the beneficial impact of clinical QOL assessment, and finally evaluate behavioural interventions that show promise to maintain or improve QOL after HCT...
  37. doi request reprint Relationships between parenting self-efficacy and distress in parents who have school-aged children and have been treated with hematopoietic stem cell transplant or have no cancer history
    Julie M Cessna
    Moffitt Cancer Center, Tampa, FL, USA
    Psychooncology 25:339-46. 2016
    ..This study sought to address this issue by comparing parents with cancer who had undergone hematopoietic stem cell transplantation (HSCT) to parents without cancer on measures of PSE and psychological distress...
  38. doi request reprint Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function
    Brian C Betts
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Sci Transl Med 9:. 2017
    ..Thus, inhibiting CD28 and IL-6 signal transduction pathways in donor T cells can increase the Treg/Tconv ratio, prevent GVHD, and preserve antitumor CTL...
  39. pmc STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity
    Brian C Betts
    1 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Leukoc Biol 95:205-13. 2014
    ..STAT3 represents a relevant target for achieving control over human alloresponses, where its suppression facilitates STAT5-mediated iTreg growth and function. ..
  40. pmc CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response
    Brian C Betts
    Departments of Blood and Marrow Transplantation, Immunology, Hematopathology and Laboratory Medicine, Drug Discovery, and Biostatistics, Analytic Microscopy Core, H Lee Moffitt Cancer Center, Tampa, Florida, USA
    J Leukoc Biol 97:807-19. 2015
    ..Future studies are needed to validate the association of STAT3 activity in acute GVHD. Novel GVHD prevention strategies that incorporate dual STAT3 and mTOR inhibition merit investigation. ..
  41. doi request reprint Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation
    Mohamed Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Division of Oncologic Sciences, University of South Florida, Tampa, Florida, USA
    Cochrane Database Syst Rev 7:CD010280. 2014
    ..Conflicting results regarding various clinical outcomes following allo-HCT have been observed when comparing mycophenolate mofetil-based regimens against methotrexate-based regimens for acute GVHD prophylaxis...
  42. pmc Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly
    Anandharaman Veerapathran
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA
    Blood 118:5671-80. 2011
    ....
  43. ncbi request reprint Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission
    Joseph Pidala
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Division of Oncologic Sciences, University of South Florida, Tampa, Florida, USA
    Cochrane Database Syst Rev 10:CD008818. 2011
    ....
  44. doi request reprint CD25 Blockade Delays Treg Reconstitution and Does Not Prevent Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
    Frederick L Locke
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL
    Biol Blood Marrow Transplant . 2016
    ..By delaying Treg reconstitution and promoting immunological memory, anti-CD25 therapy may augment alloreactivity and anti-tumor immunity...
  45. pmc Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation
    Joseph Pidala
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    Blood 124:2596-606. 2014
    ..Full matching at HLA-A, -B, -C, and -DRB1 is required for optimal unrelated donor HCT survival, and avoidance of nonpermissive HLA-DPB1 mismatches in otherwise HLA-matched pairs is indicated. ..
  46. pmc Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation
    Heather S L Jim
    Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida 33612, USA
    Cancer 118:3407-16. 2012
    ..To date, little research has investigated the cumulative effects of clinical risk factors on cognitive function in patients who undergo HCT...
  47. pmc Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management
    Heather S L Jim
    Moffitt Cancer Center, Tampa, Florida Electronic address
    Biol Blood Marrow Transplant 20:1465-84. 2014
    ..These results highlight the need for rigorous observational and interventional studies of sleep disruption and disorders in HCT recipients.. ..